Academic Reading: 3

Antibiotic Resistance and Evolution

When Alexander Fleming accepted the Nobel Prize in 1945 for his discovery of penicillin, a drug that had already transformed the treatment of previously deadly bacterial infections, he used part of his acceptance speech to issue an unusually specific warning. He cautioned that bacteria could become resistant to penicillin if the drug were used carelessly or in doses too low to kill an infection completely, potentially rendering the drug ineffective in the future. Fleming's prediction has proven remarkably accurate; antibiotic resistance is now considered one of the most serious threats to global public health.

The underlying mechanism of resistance is a straightforward, if unwelcome, illustration of natural selection operating on a rapid timescale. Bacterial populations are enormous and reproduce extremely quickly, and random mutations inevitably arise within them, some of which happen to reduce a bacterium's vulnerability to a particular antibiotic. Under normal conditions, such mutations offer no particular advantage and may even carry a slight cost. Once an antibiotic is introduced into the environment, however, the situation changes entirely: bacteria without the resistance mutation are killed off, while resistant bacteria survive and reproduce largely unopposed, quickly coming to dominate the population. Crucially, bacteria can also acquire resistance genes directly from other bacteria, including entirely different species, through a process called horizontal gene transfer, which allows resistance to spread through a bacterial community far more rapidly than ordinary reproduction alone would permit.

Human behavior has substantially accelerated this naturally occurring process. Physicians in many countries have historically prescribed antibiotics for viral infections, against which antibiotics have no effect whatsoever, partly due to patient expectations and diagnostic uncertainty. Patients who do receive an appropriate antibiotic prescription frequently stop taking the medication once they begin feeling better, rather than completing the full course, a practice that can leave behind precisely the partially resistant bacteria most likely to survive and multiply. Agriculture has compounded the problem considerably as well; for decades, antibiotics were routinely added to livestock feed not to treat illness but simply to promote faster growth, exposing enormous bacterial populations to constant, low-level antibiotic pressure that is particularly conducive to the emergence and spread of resistance. Because resistant bacteria travel readily through international trade and travel networks, experts increasingly describe antibiotic resistance as a distinctly global problem, one in which overuse in a single country can eventually affect the effectiveness of treatments available elsewhere.

In response, public health authorities in many countries have implemented antibiotic stewardship programs, which are designed to ensure that antibiotics are prescribed only when genuinely necessary and used at appropriately effective doses. Several countries have also introduced stricter regulations limiting the routine agricultural use of antibiotics for growth promotion rather than disease treatment. Developing entirely new antibiotics, meanwhile, has proven economically challenging for pharmaceutical companies, since a genuinely novel antibiotic is often deliberately reserved by physicians for the most severe cases in order to delay the emergence of resistance against it, which paradoxically limits the drug's sales and, correspondingly, the financial incentive for companies to invest heavily in developing it. Partly in response to this gap, researchers are increasingly exploring alternative approaches, such as phage therapy, which uses viruses that specifically target and destroy bacteria, as one of several potential supplements to conventional antibiotics in the years ahead.